Balyasny Asset Management
VTGN icon

Balyasny Asset Management’s VistaGen Therapeutics VTGN Stock Holding History

Balyasny Asset Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,726
Closed -$8.42K – 3196
2022
Q4 		$8.42K Buy
2,726
+1,573
+136% +$5.92K ﹤0.01% 2581
2022
Q3 		$5K Buy
+1,153
New +$11.4K ﹤0.01% 2712

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management's VTGN Position: Q1 2023 in Review

Balyasny Asset Management sold out of VistaGen Therapeutics (VTGN) in Q1 2023, closing a stake of 2,726 shares — an estimated $8.42K sold.

Balyasny Asset Management first reported a position in VTGN in Q3 2022 and held it in 2 quarters. The position peaked at $8.42K in Q4 2022. 83 funds tracked by Wall St. Rank hold VTGN as of Q1 2023.

  • Balyasny Asset Management reported no remaining VistaGen Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 2,726 VistaGen Therapeutics shares in Q1 2023, an estimated $8.42K.
  • Balyasny Asset Management first reported a position in VistaGen Therapeutics in Q3 2022 and held it in 2 quarters.
  • Balyasny Asset Management's VistaGen Therapeutics position peaked at $8.42K in Q4 2022.
  • 83 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.